A potential competition bias in the detection of safety signals from spontaneous reporting databases

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 11, 2010, Pages 1166-1171

  Pariente, Antoine ^a,b,c   Didailler, Marie ^c   Avillach, Paul ^c   Miremont Salamé, Ghada ^b,c   Fourrier Reglat, Annie ^a,b,c   Haramburu, Françoise ^b,c   Moore, Nicholas ^a,b,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM U657   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Data interpretation adverse drug reaction reporting system; Datamining; Drug safety; Pharmacovigilance; Signal detection

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BLEOMYCIN; CALCIUM CHANNEL BLOCKING AGENT; FENOFIBRATE; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; KETOCONAZOLE; NARCOTIC ANALGESIC AGENT; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SULFONAMIDE; TRIPTAN DERIVATIVE; TUBERCULOSTATIC AGENT;

ARTICLE; BLEEDING; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DRUG SAFETY; HEADACHE; HEART INFARCTION; HEPATITIS; HUMAN; HYPOTHESIS; MATHEMATICAL COMPUTING; MYALGIA; PRIORITY JOURNAL; REFERENCE DATABASE; SIGNAL DETECTION; SPONTANEOUS REPORTING DATABASE; STATISTICAL ANALYSIS; STROKE; TOXIC EPIDERMAL NECROLYSIS;

EID: 78049296017     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2022     Document Type: Article

References (34)

1. Edwards IR, Lindquist M. First, catch your signal. Drug Saf 2010; 33(4): 257-260.
2. Waller PC, Coulson RA, Wood SM. Regulatory pharmacovigilance in the United Kingdom: current principles and practice. Pharmacoepidemiol Drug Saf 1996; 5(6): 363-375.
3. Moore N. Assessing drug safety. BMJ 2005; 330(7490): 539-540.
4. Moore N, Thiessard F, Begaud B. The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 2005; 14(4): 285-286.
5. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009; 18(6): 427-436.
6. Dumouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999; 53: 177-202.
7. DuMouchel W, Smith ET, Beasley R, et al. Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. Clin Ther 2004; 26(7): 1092-1104.
8. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54(4): 315-321.
9. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10(6): 483-486.
10. Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1997; 44(5): 513-518.
11. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004; 13(8): 519-523.
12. Almenoff JS, LaCroix KK, Yuen NA, Fram D, DuMouchel W. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department. Drug Saf 2006; 29(10): 875-887.
13. Roux E, Thiessard F, Fourrier A, Begaud B, Tubert-Bitter P. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance. IEEE Trans Inf Technol Biomed 2005; 9(4): 518-527.
14. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11(1): 3-10.
15. Begaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002; 288(13): 1588.
16. Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003; 12(4): 271-281.
17. Strom LB. Pharmacoepidemiology (4th edn). Wiley: Chichester, 2005.
18. van Puijenbroek EP, van Grootheest K, Diemont WL, Leufkens HG, Egberts AC. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol 2001; 52(5): 579-86.
19. Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Arias LH. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol 1998; 54(6): 483-488.
20. Tubert-Bitter P, Haramburu F, Begaud B, Chaslerie A, Abraham E, Hagry C. Spontaneous reporting of adverse drug reactions: who reports and what? Pharmacoepidemiol Drug Saf 1998; 7(5): 323-329.
21. Pariente A, Daveluy A, Laribiere-Benard A, Miremont-Salame G, Begaud B, Moore N. Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA. Drug Saf 2009; 32(5): 441-447.
22. Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007; 30(10): 891-898.
23. Bate A, Lindquist M, Orre R, Edwards IR, Meyboom RH. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs. Eur J Clin Pharmacol 2002; 58(7): 483-490.
24. Stephens MDB, Talbot JCC, Routledge PA. Detection of New Adverse Drug Reactions (4th edn). Macmillan Reference Ltd: London, 1998.
25. Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985; 2(8463): 1056-1058.
26. Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollagnier M, Imbs JL. French pharmacovigilance database system: examples of utilisation. Therapie 1995; 50(6): 557-562.
27. Mann R, Andrews E. Pharmacovigilance (2nd edn). Wiley: Chichester, 2006.
28. Dukes M, Aronson J. Meyler's Side Effects of Drugs (14th edn). Elsevier: Amsterdam, 2000.
29. Modern Epidemiology (2nd edn) [Database on the Internet]. 2007. Available at: [accessed on 10 September 2007].
30. Trifiro G, Pariente A, Coloma PM, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf 2009; 18(12): 1176-1184.
31. Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; 94(4): 419-436, quiz 36-38, 56.
32. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331(19): 1272-1285.
33. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128(1): 35-44.
34. Hauben M. Signal detection in the pharmaceutical industry: integrating clinical and computational approaches. Drug Saf 2007; 30(7): 627-630.